{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:17Z","timestamp":1791358037030,"version":"4.3.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) can induce diverse immune-related adverse events (irAEs), but pan\u2013airway mucosal involvement is rare and may mimic common infectious laryngopharyngitis. A 76-year-old woman receiving long-term pembrolizumab for lung squamous cell carcinoma developed asthma-like symptoms ~1 year after treatment initiation, which were partially controlled with inhaled corticosteroid. Approximately 3 years after pembrolizumab initiation, she presented with persistent hoarseness and sore throat. Laryngoscopy showed diffuse erythema and a characteristic cobblestone-like appearance of the pharyngeal and laryngeal mucosa, and chest computed tomography revealed diffuse thickening of the tracheal and bronchial walls. Bronchoscopy demonstrated continuous mucosal inflammation extending from the bronchi to the larynx. Biopsies from both the larynx and trachea revealed identical dense CD8-positive T-cell infiltration without granulomatous changes, consistent with ICI-induced mucositis. Her symptoms and endoscopic and radiologic abnormalities resolved after discontinuation of pembrolizumab and initiation of oral prednisolone, and steroids were successfully tapered without recurrence. This case highlights a rare but clinically important pattern of ICI-induced pan\u2013airway mucositis, in which lower-airway inflammation may be initially attenuated by inhaled steroids and later become evident after extension to the upper airway; such airway irAEs should be considered in ICI-treated patients presenting with persistent or atypical upper-airway symptoms.<\/jats:p>","DOI":"10.1093\/jjco\/hyag016","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:34:02Z","timestamp":1768566842000},"page":"654-658","source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-induced pan\u2013airway mucositis with a cobblestone-like appearance: a case report"],"prefix":"10.1093","volume":"56","author":[{"given":"Ryo","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences , Niigata ,","place":["Japan"]},{"name":"Department of Otolaryngology, Saiseikai Niigata Hospital , Niigata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-3211","authenticated-orcid":false,"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences , Niigata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saiseikai Niigata Hospital , Niigata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazuki","family":"Kazama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saiseikai Niigata Hospital , Niigata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Horii","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences , Niigata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026050701220406300_ref1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science."},{"key":"2026050701220406300_ref2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026050701220406300_ref3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/jpm15030115","article-title":"Immune checkpoint inhibitor-induced insidiously progressive, fatal interstitial lung disease","volume":"15","author":"Kanaji","year":"2025","journal-title":"J Pers Med"},{"key":"2026050701220406300_ref4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"KEYNOTE-189 investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026050701220406300_ref5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.03.016","article-title":"Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-na\u00efve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study","volume":"150","author":"Fujimoto","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026050701220406300_ref6","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2217\/fon-2019-0102","article-title":"Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma","volume":"15","author":"Baba","year":"2019","journal-title":"Future Oncol"},{"key":"2026050701220406300_ref7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1053\/j.seminoncol.2023.01.003","article-title":"Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review","volume":"49","author":"Kawakami","year":"2022","journal-title":"Semin Oncol"},{"key":"2026050701220406300_ref8","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1002\/lary.31492","article-title":"Immune checkpoint inhibitor\u2013induced supraglottitis: A case series","volume":"134","author":"Gascon","year":"2024","journal-title":"Laryngoscope."},{"key":"2026050701220406300_ref9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell."},{"key":"2026050701220406300_ref10","doi-asserted-by":"publisher","first-page":"1615835","DOI":"10.3389\/fonc.2025.1615835","article-title":"Case report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab","volume":"15","author":"Palmeri","year":"2025","journal-title":"Front Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/654\/66630497\/hyag016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/654\/66630497\/hyag016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:22:07Z","timestamp":1778131327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/5\/654\/8444497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,29]]},"published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag016","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,29]]}}}